SELLAS Life Sciences Group (NASDAQ:SLS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) issued its earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, FiscalAI reports.

SELLAS Life Sciences Group Stock Up 5.1%

NASDAQ SLS traded up $0.25 on Thursday, hitting $5.20. 5,809,359 shares of the company were exchanged, compared to its average volume of 7,386,729. The stock has a fifty day moving average of $4.39 and a 200-day moving average of $2.85. SELLAS Life Sciences Group has a 12 month low of $0.95 and a 12 month high of $6.14.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SLS. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. Maxim Group lifted their target price on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.00.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of hedge funds have recently added to or reduced their stakes in SLS. BNP Paribas Financial Markets increased its holdings in SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares in the last quarter. Beacon Pointe Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group during the fourth quarter valued at approximately $38,000. Sei Investments Co. purchased a new position in SELLAS Life Sciences Group during the 3rd quarter worth $43,000. Great Valley Advisor Group Inc. bought a new stake in shares of SELLAS Life Sciences Group in the 2nd quarter worth $44,000. Finally, Equitable Holdings Inc. lifted its position in shares of SELLAS Life Sciences Group by 58.6% during the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.